Search
Shanghai Pharmaceuticals Receives Approval for Formoterol Fumarate Inhalation Solution Production
1 week ago /
Read about 0 minute
Author：小编
Shanghai Pharmaceuticals proudly announces that its subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical, has secured approval from the National Medical Products Administration for the production of Formoterol Fumarate Inhalation Solution. This solution is indicated for the maintenance treatment of airway obstruction in patients suffering from chronic obstructive pulmonary disease (COPD), encompassing chronic bronchitis and emphysema. To date, the company has invested approximately RMB 4.4055 million in the research and development of this vital medication.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
